Glenmark Launches Vancomycin Injection In US; Shares Fall 0.36%

Mumbai, May 18: Glenmark Pharmaceuticals announced that its U.S.-based subsidiary has launched Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial presentations in the United States market.

Glenmark Pharmaceuticals Inc., USA said the newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, marketed by Fresenius Kabi USA, LLC, according to an exchange filing submitted on Monday.

The company stated that the product has been introduced in two strengths, 500 mg/vial and 1 g/vial. The injectable antibiotic is approved for indications listed in Glenmark’s approved label in the U.S. market.

According to IQVIA sales data cited in the company release, the Vancomycin Hydrochloride for Injection USP market for the 12-month period ending March 2026 recorded annual sales of nearly $37.9 million.

Company North America president and business head, Marc Kikuchi, said the launch reflects the company’s continued focus on expanding access to affordable medicines in the US healthcare market while strengthening its injectable portfolio.

The disclosure was made through a regulatory filing with the NSE and BSE under Scrip Code 532296 and symbol GLENMARK.

Stock Market Snapshot

Glenmark share price traded lower during the morning session on May 18. The stock was trading at ₹2,317.60, down 0.36% from the previous close, as of 9:35 AM IST.

According to market data, the stock opened at ₹2,329.70 and touched ₹2,334.70, while the day’s low stood at ₹2,306. The company’s market was around ₹65,410 crore.

Investors continued to track developments in the company’s U.S. generics and injectable portfolio business amid increasing competition in regulated pharmaceutical markets.

Company Background

Glenmark Pharmaceuticals Ltd is a research-led global pharmaceutical company with operations across branded, generic and consumer healthcare segments.

The company has manufacturing facilities across multiple countries and maintains a commercial presence in more than 80 markets globally. Its therapeutic focus areas include respiratory, dermatology and oncology.

Glenmark also operates an expanding injectable and specialty portfolio in regulated international markets, particularly in North America.

Conclusion

The latest U.S. product launch adds to Glenmark’s injectable drug portfolio and strengthens its presence in the generic pharmaceutical segment in the United States.

The company continues to focus on expanding regulated market offerings through differentiated launches and portfolio diversification initiatives, as per the exchange disclosure.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_18052026085619_PR_18052026.pdf